<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16-viruses-12-00838">
 <label>16.</label>
 <element-citation publication-type="web">
  <person-group person-group-type="author">
   <name>
    <surname>Overton</surname>
    <given-names>E.T.</given-names>
   </name>
   <name>
    <surname>Orkin</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Swindells</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Arasteh</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Hern√°ndez-Mora</surname>
    <given-names>M.G.</given-names>
   </name>
   <name>
    <surname>Pokrovsky</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Girard</surname>
    <given-names>P.-M.</given-names>
   </name>
   <name>
    <surname>Oka</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Andrade-Villanueva</surname>
    <given-names>J.-F.</given-names>
   </name>
   <name>
    <surname>Richmond</surname>
    <given-names>G.J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Monthly Long-Acting Cabotegravir and Rilpivirine is Non-Inferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis from the Phase 3 ATLAS and FLAIR Studies. IAS 2019, Abstract MOPEB257</article-title>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="https://www.hivandmore.de/kongresse/ias2019/002185-Cabotegravir-IAS-2019-Week-48-Pooled-Analysis-from-ATLAS-and-FLAIR-studies.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.hivandmore.de/kongresse/ias2019/002185-Cabotegravir-IAS-2019-Week-48-Pooled-Analysis-from-ATLAS-and-FLAIR-studies.pdf</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2020-07-06">(accessed on 6 July 2020)</date-in-citation>
 </element-citation>
</ref>
